Efficacy in Patients with Dose Reduction in Combination Therapy of Peginterferon and Ribavirin for Chronic Hepatitis C

Publisher： Karger

E-ISSN： 1423-0100|51|1|1-6

ISSN： 0300-5526

Source： Intervirology, Vol.51, Iss.1, 2008-02, pp. : 1-6

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Eicosapentaenoic Acid Could Permit Maintenance of the Original Ribavirin Dose in Chronic Hepatitis C Virus Patients during the First 12 Weeks of Combination Therapy with Pegylated Interferon-α and Ribavirin

By  

Intervirology, Vol. 50, Iss. 6, 2008-02 ,pp. : 439-446

Karger

Access to resources Recommend Favorite

Extending Combination Therapy with Peginterferon plus Ribavirin for Genotype 2 Chronic Hepatitis C Virological Responders: A Pilot Study of 7 Cases

By  

Intervirology, Vol. 53, Iss. 3, 2010-03 ,pp. : 188-192

Karger

Access to resources Recommend Favorite

Incidence of Depression in Patients with Chronic Hepatitis C Receiving Combination Therapy of Pegylated Interferon-Alpha and Ribavirin

By  

Psychotherapy and Psychosomatics, Vol. 83, Iss. 5, 2014-08 ,pp. : 308-309

Karger

Access to resources Recommend Favorite

Pegylated Interferon plus Ribavirin Combination Therapy for Chronic Hepatitis C in Patients with Congenital Coagulation Disorders

By  

Acta Haematologica, Vol. 120, Iss. 2, 2008-10 ,pp. : 63-69

Karger

Access to resources Recommend Favorite

Safety and Efficacy of Combination Therapy with Pegylated Interferon Alpha-2a and Ribavirin in Treating Patients with Chronic Hepatitis C and Beta-Thalassaemia Major: A Greek Single-Center Experience

By  

Acta Haematologica, Vol. 126, Iss. 4, 2011-09 ,pp. : 231-233

Karger

Access to resources Recommend Favorite